Sanofi completes Principia Biopharma Inc. acquisition

Availability of the Q3 2020 Memorandum for modelling purposes

CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

CHMP recommends approval of MenQuadfi® for active immunization of individuals from the age of 12 months and older against invasive meningococcal ACWY disease

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Principia Biopharma Inc.

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union

Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO 

Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation